RxDoctor Payments Data

Arthur Efros, MD

Geriatric Medicine · Southfield, MINPI 1972672103

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 29.0% of the total.

$2,068in general payments, 2019–2025

Across 143 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$600
  • Amgen$187
  • Novartis$142
  • Abbott$115
  • Lilly USA, LLC$107
  • Boehringer Ingelheim$106
  • plus $812 from 17 others

What the payments were for

  • Food & beverage$2,068100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,068 in reported general payments places this provider in the 85th percentile of 168 geriatric medicine providers in Michigan.

See all geriatric medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$62,640
Medicare patients
121
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate61$85,560
RybelsusSemaglutide16$28,211
OzempicSemaglutide26$26,041
JardianceEmpagliflozin22$23,934
XareltoRivaroxaban11$17,358
Breo ElliptaFluticasone/Vilanterol36$12,982
FarxigaDapagliflozin Propanediol11$6,254
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,231
Atorvastatin Calcium247$3,570
ZocorSimvastatin26$3,486
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,355
Wixela InhubFluticasone Propion/Salmeterol12$3,316
Metoprolol Succinate147$2,959
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,915
Rosuvastatin Calcium124$2,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$50$85,56061 claims
Novo NordiskRybelsus, Ozempic$600$54,25242 claims
Boehringer IngelheimJardiance$106$23,93422 claims
GSKBreo Ellipta$48$12,98236 claims
AstraZenecaFarxiga$96$6,25411 claims
AbbVieSynthroid$68$1,23118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 geriatric medicine providers in Michigan.

Other geriatric medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →